Skipper He
Impact in
- Oncology top 5%
- Cancer Treatment and Pharmacology
- Drug Transport and Resistance Mechanisms
- Cancer Cells and Metastasis
- Cancer Research top 10%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 15
- Cancer Treatment and Pharmacology 7
-
- Cancer therapeutics and mechanisms 5
- Biochemical and Molecular Research 4
- Co-authors
- Schabel Fm (27 shared papers)Laster Wr (13 shared papers)Wilcox Ws (8 shared papers)Montgomery Ja (2 shared papers)Trader Mw (7 shared papers)Griswold Dp (5 shared papers)Linda Simpson‐Herren (5 shared papers)Corbett Th (2 shared papers)
- Journals
- PubMed (36 papers)Medical Entomology and Zoology (1 paper)
- Partner nations
- United States
In The Last Decade
Skipper He
36 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 100
- Oncology 568
- Cancer Research 225
- Hematology 167
- Modeling and Simulation 66
- Genetics 118
Countries citing papers authored by Skipper He
This map shows the geographic impact of Skipper He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Skipper He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Skipper He more than expected).
Fields of papers citing papers by Skipper He
This network shows the impact of papers produced by Skipper He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Skipper He. The network helps show where Skipper He may publish in the future.
Co-authors
The 14 scholars most cited alongside Skipper He, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. | 1963 | 328 |
| 2 | Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. | 1967 | 208 |
| 3 | Establishment of cross-resistance profiles for new agents. | 1983 | 126 |
| 4 | Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells. | 1978 | 61 |
| 5 | EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIV. FURTHER STUDY OF CERTAIN BASIC CONCEPTS UNDERLYING CHEMOTHERAPY OF LEUKEMIA. | 1965 | 60 |
| 6 | Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. | 1984 | 57 |
| 7 | Concepts for controlling drug-resistant tumor cells. | 1980 | 46 |
| 8 | Observations on the anticancer activity of 6-mercaptopurine. | 1954 | 45 |
| 9 | Success and failure in the treatment of solid tumors. II. Kinetic parameters and "cell cure" of moderately advanced carcinoma 755. | 1969 | 45 |
| 10 | Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors. | 1965 | 44 |
| 11 | Experimental evaluation of potential anticancer agents. XIX. Sensitivity of nondividing leukemic cell populations to certain classes of drugs in vivo. | 1965 | 41 |
| 12 | Combination therapy: some concepts and results. | 1974 | 39 |
| 13 | Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster. | 1968 | 34 |
| 14 | Spontaneous AK leukemia (lymphoma) as a model system. | 1969 | 30 |
| 15 | Basic and therapeutic trial results obtained in the spontaneous AK leukemia (lymphoma) model-end of 1971. | 1972 | 28 |
| 16 | Kinetic behavior versus response to chemotherapy. | 1971 | 26 |
| 17 | Experimental evaluation of potential anticancer agents. I. Quantitative therapeutic evaluation of certain purine analogs. | 1961 | 24 |
| 18 | Experimental evaluation of potential anticancer agents. 28. Effects of therapy on viability and rate of proliferation of leukemic cells in various anatomic sites. | 1965 | 22 |
| 19 | Studies on the mechanism of action and anticancer activity of N-methylformamide. | 1955 | 19 |
| 20 | Experimental evaluation of potential anticancer agents. XVI. Basic study of effects of certain anticancer agents on kinetic behavior of model bacterial cell populations. | 1965 | 14 |
About Skipper He
Skipper He is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Public Health, Environmental and Occupational Health, having authored 37 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), Acute Lymphoblastic Leukemia research (5 papers), Cancer therapeutics and mechanisms (5 papers), Lung Cancer Treatments and Mutations (5 papers), Biochemical and Molecular Research (4 papers), Nanoparticle-Based Drug Delivery (3 papers), HIV/AIDS drug development and treatment (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Oncology (568 citations), Cancer Research (225 citations), Hematology (167 citations), Modeling and Simulation (66 citations) and Genetics (118 citations). Skipper He has collaborated with scholars based in United States. Frequent co-authors include Schabel Fm, Laster Wr, Wilcox Ws, Montgomery Ja, Trader Mw, Griswold Dp, Linda Simpson‐Herren, Corbett Th, Thomson and Brockman Rw. Their work appears in journals such as PubMed and Medical Entomology and Zoology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.